“Each year, millions of Americans walk out of a doctor’s officewith a misdiagnosis. Physicians try to be systematic when identifying illness and disease, but bias creeps in. Alternatives are overlooked. Now a group of researchers in the United States and China has tested a potential remedy for all-too-human frailties: artificial intelligence.
“In a paper published in Nature Medicine, the scientists reported that they had built a system thatautomatically diagnoses common childhood conditions— from influenza to meningitis — after processing the patient’s symptoms, history, lab results, and other clinical data.”
“Recently, two AI drug design companies, Insilico Medicine and A2A Pharmaceuticals joined forces to bring to market a possible treatment for Duchenne muscular dystrophy (DMD) and other rare orphan diseases. Using AI to more rapidly discover optimal pre-clinical candidates may revolutionize the drug development process in the life sciences.”
“What AI can bring to the table is the ability to rapidly and accurately sort through massive amounts of data. This may very well revolutionize how competitive intelligence, drug discovery and stakeholder engagement take place as we know it. Among many functions that medical affairs is tasked with, an important one is stakeholder engagement with External Experts (EE) (formerly known as KOLs or Key Opinion Leaders). For Medical Science Liaisons (MSLs), who are the primary function engaging external stakeholders, there will likely be several changes.”